Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Conference · 2026-11-17
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Open the source you need; every reader stays inside this workspace.
Good morning, everyone. Thank you so much for joining us on our next session. I'm Michael Yee, Global Head of Biotech Research at UBS, and I'm very excited to have the team from First Tracks Biotherapeutics here with us at the conference, specifically President and Chief Executive Officer Dan Faga up here with us.
Dan, thank you for joining us.
It's a pleasure to have you at our conference.
Thank you very much. Nice to be here.
Well, let's start with the fact that First Tracks has... I've been putting up some great data with your lead program, a CD122 antagonist antibody, for many autoimmune diseases, but specifically in celiac disease. And so if I could have you just briefly introduce the company to the audience. Here we are in London, so broadening out the investor base, and I would love for you to explain to everybody what ANB033 is and what makes it unique.
Thank you very much. Nice to see everyone here today. Representing First Tracks Bio, here goes by Tracks. We have three clinical stage I&I programs within the company, as well as a research platform. We're a new company. We spun out from our predecessor about six, eight months ago. And then to your point with our lead program, AMB-033, this is a CD122 antagonist for celiac disease and EUE, amongst other targets or indications that we'll be talking about. We did recently announce top-line results from our first of two ongoing celiac trials. So really exciting results. First time in the treatments in this disease where there is no approved therapeutics, where we saw an impact both on mucosal injury of C-like disease as well as on symptoms. So it's an exciting start to the story here at First Tracks. We have a number of catalysts already lined up for next year across all three of our programs.
Before we get into all three of the programs, let's focus on at least the LEAD program, of course, which had data recently. And there's been a lot of focus on this class because the year of 2026 was the year that three companies at least have put up various degrees of phase one data. And celiac disease and all the three molecules are at least somewhat similar in terms of mechanism. Can you explain how you think about the three different programs and how you think about your program as differentiated from the others? Do you think it's better than theirs? Do you think it is more potent? Well, how do you think about that? Because Argenix just acquired Forte. Paid about $2 billion, $2 billion, and put up some good data in phase one. And obviously, Teva put up some good data as well. And their stock traded up. In fact, they just had an R&D day and spent a lot of time talking about this. So tell us about yours. And is your program differentiated and perhaps superior?
As these things go, there is a lot of competitive data right now in the space, and I think when you step back and you look across these three different programs you just cited, we've all had positive data in celiac disease, and what I said in my opening remarks, there's nothing approved in celiac disease today, so I think we're on to something right now in terms of actually targeting the biology of this disease for the first time directly. So historical approaches generally focused or centered on the targeting of gluten, the antigen within celiac disease. What we do with a CD122 antagonist is we are binding two different T cells that are lit up in this inflammatory cycle. We specifically block the signaling of both IL-15 and IL-2. So this is a dual mechanism antagonist. One of our competitors, Argenix, has a similar targeted drug. Teva is only targeting one of those two cytokines. They target IL-15 directly. Now, what's important here is when your body, if you have celiac disease, and you meet with gluten, it presents itself downstream with gliadin. APCs pick it up and activate CD4 cells. These CD4 cells initiate the inflammatory cycle. What we're doing with the CD122 is we're able to shut down the proliferation and the cytokine secretion of those CD4 cells by blocking IL-2. That's differentiated from the IL-15s only. IL-15 is really important in this disease. It facilitates the destruction of the epithelial layer, which is the destruction of villi, which absorbs nutrients in celiac disease. So it's another immune pathway within celiac. So, these drugs are all working relative to each other, but the CD122s are dual mechanism, and what we observed in our clinical data is not just, as I mentioned earlier, an impact on mucosal injury, but also on symptom prevention. That symptom of prevention is likely directly tied to the fact we're blocking IL-2 signaling. So we have a very potent CD122 antagonist. We do think there's a potency difference on the affinity and the way we bind on these cells relative to our competitors, our GenX. And at least for today, maybe temporarily at least, we have a difference in the administration of our drugs. We are subcutaneously administered. Our competitor is IV. So there's differences here in potency.
Let me repeat it again. So are GenX, Forte, their IV administration?
That is correct.
Okay. And your phase one that just completed, that was sub-Q syringe start? Yes. And you believe that would be able to be dosed in a pen, I'm sure.
At some point in the future, there's no technical reason that won't happen. Okay.
And then Teva's program, is there sub-Q or IV?
It's subcutaneously administered, but a different mechanism.
Right. Okay. Fantastic. And so can you explain the upcoming data, appreciating that for the audience here, but all three of these companies have put up positive phase 1B gluten challenge data, okay? Again, in the simplicity of this form, in a placebo-controlled gluten challenge, you showed significant improvements in the VHCD endpoint. But this upcoming study, Dan, is in a different population where we're not doing a gluten challenge. So describe the study, and what kind of results would you expect in this study? Because no one else has done the study.
I actually want to take a minute and actually describe our gluten challenge results. Okay, we can do that, too. A little bit more detail will tee up a little bit what you're asking about. So to Mike's point, we ran two different studies. So patients who are well-controlled on a gluten-free diet. We ran a gluten challenge study. We actually ministered on one-to-one randomization gluten to these patients. Patients on the control arm, on placebo, you would expect them to get worse. It was an intense gluten challenge. They got a lot worse. This was over a 14-day period. We gave the equivalent of two to three slices of bread a day. On drug, we saw, in the context of an intense gluten challenge, almost a full prevention of deterioration. So on VHCD, villocyte to crypt depth ratio, the measurement of the villi that I was speaking to earlier that are getting destroyed in the context of gluten, we saw two things. The delta from the control arm was a 0.5. That's best in disease right now across the entire competitive landscape. The second thing, and almost more important, now that we've established this as an intense gluten challenge, we prevented deterioration on our drug. Only a minus 0.17 on the VHCD ratio. This is considered to be meaningfully lower than a clinically meaningful level of deterioration. So that's really important in a vacuum there. But what I mentioned earlier on symptoms, patients who took our drug relative to their baseline level coming into the trial, there's no increase in symptoms on acute contact of gluten. Whereas on the drug arm, there's a significant increase. We saw a statistic difference on the entirety of how we measure symptoms using the CDSD, which is a daily diary of the severity across four different GI domains and fatigue. And then importantly, half of the patients on placebo also took concomitant medicines to help manage down their symptoms. So we still saw a statistically significant difference. It held over the course of that first week, regardless of the fact that placebo patients were taking these other drugs. And for moderate and severe symptoms, we saw a stat state difference through the first 12 days of the 14-day gluten challenge. So in totality here, and then when you look at the AEs, we had a clean, safety, tolerability profile of the drug. But the patients on placebo, as you would expect, saw a lot of AEs. We're giving them gluten. So the importance of this, of showing the histological and symptom benefit, has never been seen before. And we're doing both of those components. So now what's different with the next trial? So we, uniquely, relative to the competitive field, are running a second trial. That reads out in the first quarter of next year. It's fully enrolled. And instead of giving a gluten challenge, the patients we're enrolling in the second cohort are more severe. They were unable to take gluten in the context here. They had too much damage in rucosal injury. What we're looking to do with these patients, instead of protect them, we're looking to actually heal their rucosal injury. So the side of the expectations, there won't be anything on symptoms. These patients are asymptomatic or low symptoms at baseline. They actually thought they were preserved on a gluten-free diet. They found out via biopsy in the trial that they had this damage. And so there's long-term consequences of malabsorption. So what we're trying to do here, there won't be a symptom difference, but actually improve the outcome. So over a period of 12 weeks, we have a loading dose subcutaneously for the first month. At baseline, week two, week four, we're waiting eight weeks off the drug. We're doing a biopsy week 12, and we're going to look and see if we've improved the VHCD for half of the patients that are on drug relative to the one-to-one randomization and the other half of patients on placebo. The expectations here, I don't know if we need to see statistical significance. It might take six months, nine months to actually truly fully heal a patient. We're looking at translational data, impact on the T cells to show that we're clearing out the inflammation. And we're looking for a numerical change on VHCD relative to the control arm that we're showing that benefit in that first three-month period. So it's an exciting second study, and I really think it sets up two different registration enabling paths to take this drug forward.
Okay, so let's unpack that a little bit. So in this study, which no one else has run yet, you are taking patients who specifically have a VHCD, help me remember, below 2.5.
That's correct. So moderate to severe, severe baseline injury.
And like below two, is there like some specific cutoff of these are patients who are...
This theoretically can go to zero. Patients don't go to zero.
But below two, it's pretty bad.
More than half the patients will be less than 2.0 at baseline. And for context, in the gluten challenge study, the baseline median was 2.7.
Got it. Okay. And so these patients are randomized one-to-one to placebo injections or your drug at baseline. And I think you said two, four, six.
Zero, two, and four. Zero, two, and four. And then eight weeks off of drugs.
And then we watched them for eight weeks. These are patients who are in a gluten-controlled diet, meaning they're doing their best every day to not see any gluten.
An inclusion criteria was for 12 months, at least, they've been on a gluten-free diet. But this is the irony of it. You get exposed in this population to gluten. These patients did not realize they had the severe damage. You eat a breadcrumb and it initiates the cycle.
Okay, so when you run this study, you expect that the placebo arm over this period, because even though they're doing the best to have a gluten-controlled diet, they could still be getting damage to their villi, and the VHCD is going down. And then on the drug arm, you could be improving the VHCD because there's recovery of the villi and there's healing.
We don't know what we're going to see in the control arm. One's going down, one's going up. We don't know what to see in the control arm. It hasn't been done before. Some patients might get a little bit worse. Some patients might get a little bit better. And then we presume that in the course of years on the control arm of patients or stayed on a gluten-free diet, they'll get better. We're looking to rapidly accelerate that.
Well, it is true that we don't really know. Now, what I would say, and again, this is different because in the gluten challenges, you're giving them gluten. They're literally drinking this as a challenge test. And in here, we're not doing anything. They're going home and living their normal life, and we're just going to observe. Now, what I understand is that generally because you eat a breadcrum, you're just exposed to it over this period of time, you could be seeing some damage over time. Do they see symptoms, or no, they're not because they're trying to stay away, but you're going to see a little bit.
Like I said, these patients thought they were controlled. They actually had exposure prior without realizing it and created the damage. So I don't want to get too much in the weeds on this. We expect to see the patients on drug do better than on the control. What we don't know is it will take longer than three months. We're looking for a leading indicator. We don't have to be stat sig, and the reason I'm saying it this way is a future trial is a phase one trial. A future trial will be six months to a year. You have a lot longer to then measure and improve on patients.
Now, the reason I say that we could be getting better, and I guess I agree with you that we just want to do better than the placebo, is because you're initiating protection by giving them the drug, which is shutting down those T-cells, which is what is causing the damage.
So let's pull this together.
So philosophically, you should be giving them protection.
We can give you gluten, and we can protect you. Hopefully, we can then treat you and make you better. So we talk a lot now around two paths forward, registration enabling trials. There's nothing approved here. If we had this discussion a year ago, we would have been very much focused, where big pharma historically has been focused, on this healing study, making patients better. What's been unearthed this year, and really through discussions with the agencies of myself and our competitors, there's been really productive preliminary discussions where there's now a second path. You can take one path or the other, but ideally you can take both, or you can look at getting a label, like I mentioned earlier, preventing damage in the context of the presence of gluten. This doesn't mean that you're off a gluten-free diet. Now, these challenges we're talking about, two, three slices of bread a day for 14 days, that's in a clinical study. The first step here is preventing damage in the context of staying on your gluten-free diet and allowing patients to go live a more normal life. But the second path towards healing, if you put that together, you can now treat pretty much anyone with celiac disease. If you could then pursue each individually and get a label that encompasses all patients. That's... That's a very, very big market opportunity.
Is this pretty new? Because there is an FDA guidance document that is fairly old, but it was about the first part, which is ensuring that there is a improvement and that you are doing this in these patients because, again, I could pharmacoeconomically support why we want to keep people from 2.5 going down to 2 is because they have this ongoing disease. There's ongoing damage. They're staying away from gluten, and yet their VHCD is going down to a level below two where we could start having malnutrition, and it's going to get pretty bad. So there's a pharmacoeconomic value to be had there.
There's a well-accepted long-term impact of fatigue on quality of life, osteoporosis, certain types of bone cancers. There's real severe long-term consequences that we're looking to prevent, no different than a lot of other broader GI or IBD diseases. So you're referring to draft FDA guidance from four to six years ago, which, like I mentioned, prior big pharma companies focused in the space were primarily focused on healing. So there's no draft guidance for the second registrational path, but from read-through from discussions with our competitors, I'm saying very directly, we've all gotten feedback that this other path exists. Meaning the more gluten-challenged type, yes. On a prevention pathway.
Right, right. And so that would be, and so what would that design look like? Is that more of a gluten-challenged type thing, or that's just people with higher VHCD?
There's still things to very directly lock in. We are one month removed from our data showing prevention. We will discuss with the agency next year to get the specifics of how much gluten are you giving? When are you giving in the context of a longer trial that will go out six months to a year? When we think about the program overall. We need to drive towards a safety database, regardless of how many Phase 2b3 trials we're doing. That's going to be the driver of how large the program is, out with one year of exposure. And then you're asking good questions, some of the details between. That'll play out through some discussions. I wouldn't think about that as risk. We have lots of good ideas of how to go administer glue. We just showed how you can go do that. We just need to go show our data, have the discussions, lock in a couple of the variables.
How do you think about this in 2027 in the context that TEVA has announced they're going forward, they like their program, and they're going to do some more studies, including a Phase 2B starting up. And as we understand, since UBS covers our Gen X, they say they're moving directly into a phase three. I don't understand the details of this, but maybe you could help the audience because your two competitors are advancing forward. I'm not clear on the exact details of what they're doing. Maybe you could help us understand what you've heard and what are you going to do?
I'll focus, I think, more on where we're going.
Well, I don't know what they're doing.
It's hard to distinguish between the different languages. I think Teva overall had a positive result. They showed a positive delta on VHCD. Their drug was less protective. They saw a minus 0.4 on active. We showed a minus 0.17. That's a material difference in the protection in the control arm. On symptoms, neither of the other competitors have presented the detailed data. It does not seem like they hit statistical significance on symptoms. I think there's very different results, even though we're all positive in general. That's going to lead to likely different conclusions of how you're going to take your drug forward, and people are using different language. What we've said publicly is we're moving to late-stage trials.
Okay. Late-stage trials.
Okay. Right. And the reason I'm using that language is I want to go speak with the regulators first and specifically work through the designs of how to move this program towards commercialization over the next number of years. We tested one dose. It was a high, no-regret dose, and we had great results. What that allows us to do in future studies is also look at lower dosing. So we're going to want to assess lower doses beyond where we started. Drug was safe, tolerable, no issues with it. Right now, it technically would be looked at as an every-other-week dose. But in the second cohort, like I mentioned earlier, we're already looking at Q8 week. So I think we have a lot of flexibility here to look at longer-term maintenance-based-out dosing. That's something we're going to explore in later-stage trials in parallel to our station-ablium. So I think we all have different terminology, but this will all get clarified more specifically next year.
Thank you for clarifying that. And it's interesting because I do think that there's been a lot of enthusiasm and a lot of interest across this. I think people are even trying to do YTE antibodies for this, too. So, you know, I do think that once you're interested— It's interesting you say it like that.
We have a long-term PD effect with our first-generation molecule. So I'm just going to repeat it. We are already looking at Q8-week dosing. Okay. Right? In our second cohort. Just by definition. We are highly confident based on our tox data, animal models, animal studies that we've looked at, As well as our phase 1A in healthy volunteers, that we will be above the IC90 off of our loading dose through that 12th week, 8 weeks off drug, in the tissue. So we have a lot of flexibility here with first generation, but long PD. So the effect of a YTE version, this is different from going from weekly dosing in a disease like EUE, or every other weak dosing in disease like atopic dermatitis, when you look at Dupixin, relative to a long-acting YTIL-13 that can go to quarterly dosing. We're already directionally there.
Right, because of the PD effect. Because of the PD effect. Exactly. With Apogee and these others, that is a direct antibody that hits that, and once it's gone, obviously it's open for signaling.
There is going to be copycats behind us. It speaks to the validation of the market and what you're doing. Which is exciting, and we'll talk a little bit for a few minutes, I hope, about the broader opportunities. But next-generation drugs don't look like they're going to be differentiated when we look over. And that's a very big difference.
Because if I hear about this or YTE, you're going to hear about this. Yeah, you're going to hear about it.
Everybody heard it here. I don't think it matters.
That the PD effect of your drug is long-acting, so it doesn't matter.
But this is why there's going to be copycats. We've sat here for 20 minutes to talk about celiac disease. We have a trial ongoing in EOE that reads out in eosinophils, esophagitis. That reads out in Q3 next year. I'll get into a couple more details about that. We've also committed to starting a third trial in vitiligo. So both of the competitors, the IL-15 and the C2-122, have both shown positive results in vitiligo in a proof-of-concept study that ran out this summer. That will be our third indication. There's reason to believe the C2-122s could be differentiated there as well over the IL-15s for similar conceptual reasons of celiac. We're committed to a fourth indication.
Because of expression in skin?
Yeah, because of the expression on CD4 cells as well, that the alpha-15s won't hit, as well as in TRMs, resident memory T cells. As these like vitiligo... That could come and go in terms of the lack of pigmentation. It's always similarly coming in the same spots. That's resident memory T cells interacting and destroying melanocytes.
Interesting.
So at a high level. There's indications within GI. There's indications with DERM, Vitiligo. We have a fourth indication that remains undisclosed to initiate in the first half of next year. It has everything to do with the competitive environment that we're in. But across the three competitors, the two competitors we've talked about, there's a fourth with Novartis and ourselves. We're already all in six indications. So there's a much broader landscape of diseases. When you pipeline a product, we're actually seeing that play out real time across the diversity of the folks right now in clinical development. There's a lot of opportunities. So back to EOE, that trial is ongoing for us. It's a 50-patient, Phase I-B. We're powered to see an effect both on reduction of eosinophils, which are recruited into this disease in the context of inflammation in the esophagus. We're looking to reduce those eosinophils. By interacting the disease upstream, similar with Dupixent, the only approved biologic for EOE, acts on CD4 T-cells as well as ICTs. We should see that as well based on the animal data that we presented. We also have an effect on the CD8 cells. Patients who don't work well on Dupi, guess what? They have a high influx of CD8 cells in IL-15. So we're doing both. So we think we have a reasonable chance of reducing the eosinophil counts as well as reducing symptoms in this disease, which are the two cool primary endpoints. That'll read out in Q3. Dupixent, the only approved drug in the United States for this disease, did over $3 billion of revenue in EOE alone last year. And that's a rapidly growing double-digit market.
Didn't T-slip, tezapelumab also have some positive EOS?
What's interesting about that is they were stat-sig on both EOS reduction symptoms, much lower impact on symptoms than Dupy. But there's a big need here. You know, T-slip. Dupy is a cytokine that activates ILC2s, one of the target cells that we're looking to deactivate on one component of those immune pathways. So similar to Dupy, what we are going to offer with our drug is a different mechanism altogether that does two different things and really give hope to the patients who don't see a result on Dupy. The second line market here, if that's all we ever play in, is very, very big.
It is very big, and what I've noticed is that since my European pharma team is here, I see Novartis and also Ateva and now Argenix all have gone into this, and they're all pretty big companies. To what extent does business development, have you seen interest in that space from a partnering perspective? You know, how do you think about that? Because running four indications costs a lot of money. Maybe you have a lot of money.
We have a lot of money. You have good money, but, you know. We have three years of cash. Does that fully fund all those phase twos? It fully funds, obviously, the readouts next year in celiac and EOE. It fully funds the two additional indications, vitiligo, and the fourth indication through readout, and it funds through our initial late-stage trial in celiac disease. You'll always need more money. We have a successful drug so far. We think we'll see continued success. That's how you build value in this sector. I could not credibly sit here and tell you we could go bring to market a drug in arthritis or atopic dermatitis. There is nothing approved in celiac. It's a subset of GIs. EOE, we have one real competitor. Teva, Argenix, Novartis are not playing in EOE right now with their drugs. We are in a lead position there moving forward very quickly. Vitiligo, there's no approved biologics. So this is competitive, but we're talking about two or three companies. It's not like there's five, six, seven, eight therapeutics approved in these diseases that are all big pharma, and in these other diseases, as mentioned, 20 to 30 competitors. So the competitive intensity here is interesting with... But not across every one of those indications. But now I'll double down on it. I think we have the best drug, and that still makes a big difference in our world. Best drug, lead position, no one in front of us, and these markets are, generally speaking, untapped with a lot of patient need. When you're a biotech company, that's exactly what you're looking for to create long-term value. It doesn't mean that we're going to go into our fifth, sixth, seventh, eighth, ninth indication. At some point, if those opportunities are present, we'll have to think about how to appropriately enter the markets, but we could build a lot of value by just executing well on CELAC, EOE, and the other two indications.
Thank you. I heard it. He said best drug across the competitive landscape. Remember, I started with that as the first question.
Potentially best drug. My GC is hearing me. Did he say potentially? I just modified it.
Potentially best drug. In the last minute or so, we have spent a lot of time looking at BDC A2 modulators through everyone's focus around Biogen's litofilumab. Royalty Pharma took our royalty and bought a royalty on Biogen's drug. They're bullish on that. Biogen's bullish. Wall Street's pretty bullish. We're bullish. But you also have one.
We do.
And what stage is yours? So if this litafelumab works, this is a positive read-through to you.
We're earlier. We recently completed a Phase 1A trial on Healthy Volunteers, but it showed us some pretty important things. We're talking about BDCA2 modulation. We have a differentiated PD effect with a long half-life. As well as we are a depleter of plasma cytoid dendritic cells. So BDCA2 expresses principally on plasma cytoid dendritic cells, which are, generally speaking, found in autoimmune diseases. You don't see them much in healthy tissue. You see them in small quantities. So Biogen has two big reouts in SLE in the earlier half of December. And then importantly, I think it's in Q1 of next year, in CLE. There's nothing approved in CLE. It's a subset of lupus with a cutaneous, so it's a skin presentation. We're going to wait for those results to come out. We will talk about where we're going with our drug. We think we have a highly differentiated PD effect with our BDCA2.
Meaning you could be less frequently dosed.
Yeah, so it's not a me too. It's less frequent dosing. But it's also depletion of these cells. Biogen interacts with the cells. It gets internalized. The cells are still activated. So we actually have a slightly different mechanism, actually, even though it's the same target. We'll present our data in Phase Ia at a medical conference next year and post-biogen results, come out and talk a little bit more with where we're going to go in the development of our drug.
All right. So stay tuned for the Biogen results. That's great. We're also going to stay tuned for your data in Q1. Now, in terms of the Q1 readout, I understand. For celiac disease. Can you help us out there? Because you did say it's completed enrollment. We had done some math that it was done a bit ago. So actually, if it's a 12-week study, the data could come out as early as January at that other conference in California.
We announced in our earnings cycle when we were done with enrollment. It's a 12-week study, and you need to do something after that. Meaning it could have been before you put out the earnings. So our guidance is for Q1.
All right. We'll check with that, because I'm just saying you can do the math. It could be early Q1.
I plan celebrating New Year's Eve, not announcing data. But it will be later.
It will not be New Year's Eve, but it could be right after that. Thank you, guys, everybody.
Appreciate it.
Thank you.